Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis

Bodur, Hatice; Eser, Filiz; Konca, Şefika; Arıkan, Serpil
February 2009
Rheumatology International;Feb2009, Vol. 29 Issue 4, p451
Academic Journal
Infliximab is a chimerical monoclonal antibody currently used in the treatment of various inflammatory diseases. Lupus-like syndrome is a rarely reported adverse event, and generally observed in rheumatoid arthritis cases. We hereby define and describe a case of a lupus-like syndrome, which developed following the 4th infliximab infusion in a 62-year-old patient with ankylosing spondylitis (AS). As far as we acknowledge, the present case is the third AS case with infliximab-induced lupus.


Related Articles

  • Tumour necrosis factor inhibitor-related lupus: safety of switching agents. Luong, Jessica M. T.; Tan, Boon T.; Buchanan, Russell R. C.; Schachna, Lionel // Clinical Rheumatology;May2010, Vol. 29 Issue 5, p551 

    An increase in reports of systemic lupus erythematosus (SLE) related to tumour necrosis factor inhibitor (TNFi) therapy has recently been highlighted. We report new-onset SLE in a 22-year-old woman after 13 months of infliximab for ankylosing spondylitis (AS). Lupus symptoms promptly resolved...

  • TRATAMENTUL CU INFLIXIMAB ÃŽN SPONDILITA ANCHILOZANTÄ‚. Roşca, Corina; Berghea, Florin; Abobului, M.; Vlad, Violeta; Bojincă, Violeta; Opriş, Daniela; Negru, Magda; Constantinescu, C.; Predeţeanu, Denisa; Ionescu, Ruxandra // Romanian Journal of Rheumatology;2010, Vol. 19 Issue 4, p218 

    Infliximab (IFX) is an IgG1k anti TNFa chimerical monoclonal antibody. Presuming that TNFa is a key-element implied in the autoimmune reaction in ankylosing spondylitis (AS), several clinical studies have shown a rapid effect, sustained efficacy, the stop of the radiological progression,...

  • Anti-tumour necrosis factor therapy for ankylosing spondylitis—unresolved issues. JOIS, R. N.; GAFFNEY, K.; KEAT, A. // Rheumatology;Jun2007, Vol. 46 Issue 6, p899 

    The authors comment on issues related to anti-tumour necrosis factor (TNF) therapy for ankylosing spondylitis (AS). They state that there are evidence that treatment with infliximab, etanercept and adalimumab reduces pain and stiffness and improves the sense of well-being and functional outcome...

  • Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. WAILOO, ALLAN; BANSBACK, NICK; CHILCOTT, JIM // Rheumatology;Feb2008, Vol. 47 Issue 2, p119 

    The authors explore evidence on the cost-effectiveness of infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis (AS). They note studies commissioned by Wyeth, Abbott and Schering Plough showing that tumor necrosis factor-α inhibitors are cost-effective than...

  • Psoriasis Induced by Tumor Necrosis Factor-Alpha Antagonist Therapy: Case Series and Literature Overview. Sarpel, Tunay; Başaran, Sibel; Akçam, Filiz Doğan; Günaştı, Suhan; Denli, Yaşargül // Turkish Journal of Rheumatology;Jun2010, Vol. 25 Issue 2, p91 

    Although tumor necrosis factor-alpha (TNF-α) antagonists are shown to be effective in the treatment of psoriasis, induction of psoriatic skin lesions have been seen in patients with different rheumatic conditions who were treated with TNF-αantagonists. In this case series, we report four...

  • Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Matsuda, Junko; Kaburaki, Toshikatsu; Kobayashi, Shigeto; Numaga, Jiro // Japanese Journal of Ophthalmology;Jan2013, Vol. 57 Issue 1, p104 

    Background: We describe a HLA-B27-positive Japanese man with recurrent severe anterior uveitis OU and ankylosing spondylitis (AS) who was successfully treated with infliximab. Case: A 25-year-old HLA-B27-positive Japanese man presented with recurrent anterior uveitis OU. The symptoms were...

  • Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect. Genre, Fernanda; López-Mejías, Raquel; Rueda-Gotor, Javier; Miranda-Filloy, José A.; Ubilla, Begoña; Carnero-López, Beatriz; Palmou-Fontana, Natalia; Gómez-Acebo, Inés; Blanco, Ricardo; Pina, Trinitario; Ochoa, Rodrigo; González-Juanatey, Carlos; Llorca, Javier; González-Gay, Miguel A. // Mediators of Inflammation;2014, Vol. 2014, p1 

    Objective. TRAIL is a potential biomarker of cardiovascular (CV) disease. Ankylosing spondylitis (AS) is a chronic inflammatory disease associated with metabolic syndrome (MeS) and accelerated atherosclerosis. We assessed whether disease activity, systemic inflammation, and MeS features were...

  • Development of leprosy in a patient with ankylosing spondylitis during the infliximab treatment: reactivation of a latent infection? Lopes, Roberta Vilela; Ohashi, Claudia Barros; Cavaleiro, Luiza Helena; Cruz, Rosana de Britto Pereira; da Veiga, Rossana Ruth Garcia; Miranda, Mário Fernando Ribeiro; Yoshikawa, Gilberto Toshimitsu // Clinical Rheumatology;May2009, Vol. 28 Issue 5, p615 

    The use of tumor necrosis factor α as a treatment for chronic inflammatory conditions has been shown to be associated with an increased risk of developing infections, especially Mycobacterium tuberculosis, atypical mycobacteria, and other microorganisms. We report the case of a 58-year-old...

  • Golimumab: A human anti-TNF-alpha monoclonal antibody for the treatment of autoimmune joint diseases. Phung, Olivia J.; Coleman, Craig I. // Formulary;Sep2009, Vol. 44 Issue 9, p264 

    Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), in clinical trials, subcutaneous (SC) golimumab injected every 4 weeks...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics